Aegerion Pharmaceuticals, Inc. Announces Publication in the Lancet of Data From Its Pivotal Phase III Study of Lomitapide in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Published: Nov 02, 2012

CAMBRIDGE, Mass., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, today announced publication in the November 2nd online version of the Lancet of the 78 week data from the Company's pivotal Phase III study of lomitapide in adults patients with homozygous familial hypercholesterolemia (HoFH).

Back to news